Preparation and Characterization of Liquisolid Compacts for Improved Dissolution of Telmisartan

Table 4

Dissolution parameters of plain drug, marketed product, and LSC formulation.

Dissolution parameter	0.1 N HCl			ABS (0.5% SLS)			PBS (0.5% SLS)
	PD	MT	F1	PD	MT	F1	PD	MT	F1
(%)	70.41 ± 2.54	25.93 ± 4.60	96.08 ± 2.53	57.35 ± 1.18	69.28 ± 4.46	102.12 ± 3.54	45.01 ± 7.73	75.33 ± 2.02	96.31 ± 1.24
(%)	71.82 ± 3.32	46.30 ± 4.38	103.6 ± 1.61	64.85 ± 3.72	78.15 ± 5.07	102.12 ± 3.54	65.62 ± 2.66	82.90 ± 2.89	106.5 ± 6.2
DE30 (%)	9.44 ± 0.44	1.96 ± 0.74	100 ± 1.38	9.97 ± 0.12	40.61 ± 0.83	100 ± 1.14	6.93 ± 0.69	25.57 ± 0.02	100 ± 1.66
MDT (min)	32.02 ± 0.20	62.97 ± 2.86	4.78 ± 0.17	22.03 ± 1.82	13.65 ± 1.62	3.35 ± 0.6	38.13 ± 2.36	72.51 ± 4.44	4.36 ± 1.86

PD: plain drug.
MT: marketed tablet.
F1: optimized LSC formulation (refer Table 1 for composition).